{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-025754","form_type":"8-K","ticker":null,"cik":"0001708331","company_name":"Virpax Pharmaceuticals, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.192386+00:00","generated_at":"2026-06-04T07:56:56.989662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Virpax FY2023 operating loss narrows to $15.2M; cash at $9.1M","bullets":["Operating loss of $15.2M vs $21.7M in 2022; R&D expenses halved to $5.1M.","Cash and cash equivalents $9.1M at Dec 31, 2023, down from $19.0M a year earlier.","Regained Nasdaq compliance on March 18, 2024, after 1-for-10 reverse stock split effective March 1.","Litigation settlement with Sorrento/Scilex approved by bankruptcy court; initial payment made March 18, 2024.","CEO change: Anthony Mack resigned Nov 17, 2023; Gerald Bruce appointed CEO and Eric Floyd Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-025754","json":"https://secwatch.observer/filing/0001213900-24-025754.json","markdown":"https://secwatch.observer/filing/0001213900-24-025754.md","text":"https://secwatch.observer/filing/0001213900-24-025754.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024025754/0001213900-24-025754-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024025754/ea0202550-8k_virpax.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:56:56.989662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08fe8f010f0dc6820cc4e9ce4219cfc6f85209fb","claim":"Virpax Pharmaceuticals, Inc. reported financial results for twelve months ended December 31, 2023.","evidence_excerpt":"On March 26, 2024, Virpax Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”), issued a press release that included financial information for its fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024025754/0001213900-24-025754-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}